Table 1.
Baseline characteristics, treatment, and outcome of six patients with severe COVID‐19 pneumonia treated with corticosteroids
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | |
|---|---|---|---|---|---|---|
| Baseline characteristics | ||||||
| Age, y | 45 | 62 | 64 | 60 | 45 | 56 |
| Sex | Male | Female | Male | Male | Male | Male |
| Smoking status, smoker | Ex | Never | Never | Ex | Ex | Never |
| Comorbidities | None | Hyper‐lipidemia | None | AH radical prostatectomy nephrolithiasis | Allergic rhinitis | None |
| Disease time course | ||||||
| Time from illness onset to admission, d | 7 | 8 | 12 | 7 | 7 | 6 |
| Time from admission to ARDS, d | 2 | 0 | 1 | 1 | 2 | 3 |
| Treatment | ||||||
| Hydroxychloroquine | Noa | Noa | Noa | Yes | Noa | Yes |
| Azithromycin | No | Yes | Yes | Yes | Yes | Yes |
| Time from admission to CS treatment onset, d | 3 | 4 | 1 | 2 | 4 | 3 |
| CS treatment duration, d | 3 | 3 | 3 | 3 | 5 | 5 |
| Outcome | ||||||
| Time from CS onset to PaO2/FiO2 > 300 mm Hg, d | 9 | 14 | 6 | 11 | 18 | 13 |
| CS side effects | None | None | None | None | Hyper‐glycemia | None |
| Length of hospital stay, d | 15 | 21 | 10 | 13 | 23 | 19 |
| Viral clearance, d | NA | 20 | NA | 13 | 19 | 17 |
Abbreviations: ARDS, acute respiratory distress syndrome; AH, arterial hypertension; CS, corticosteroids; NA, not available.
a
Glucose‐6‐phosphate dehydrogenase (G6PD) deficiency.